PTK2 and urinary bladder carcinoma: found that HHT exhibited a stronger inhibitory activity than cisplatin, carboplatin, and doxorubicin in acting on bladder cancer; integrin α5β1 played a role in the resistance of bladder cancer to HHT treatment by extinguishing the integrin 5β1-FAK/Src axis.